Format

Send to

Choose Destination
See comment in PubMed Commons below
Mol Ther. 2014 Jan;22(1):92-101. doi: 10.1038/mt.2013.233. Epub 2013 Oct 3.

Knockdown of β-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo.

Author information

1
Dicerna Pharmaceuticals, Watertown, Massachusetts, USA.
2
1] Dicerna Pharmaceuticals, Watertown, Massachusetts, USA [2] Current addresses: Shire Human Genetic Therapies, Lexington, Massachusetts, USA (S.K.B.); Acceleron Pharma, Cambridge, Massachusetts, USA (M.L.); Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts, USA (Y.L.); Medivation, San Francisco, California, USA (D.H.W.).
3
Integrated DNA Technologies, Coralville, Iowa, USA.

Abstract

Despite progress in identifying molecular drivers of cancer, it has been difficult to translate this knowledge into new therapies, because many of the causal proteins cannot be inhibited by conventional small molecule therapeutics. RNA interference (RNAi), which uses small RNAs to inhibit gene expression, provides a promising alternative to reach traditionally undruggable protein targets by shutting off their expression at the messenger RNA (mRNA) level. Challenges for realizing the potential of RNAi have included identifying the appropriate genes to target and achieving sufficient knockdown in tumors. We have developed high-potency Dicer-substrate short-interfering RNAs (DsiRNAs) targeting β-catenin and delivered these in vivo using lipid nanoparticles, resulting in significant reduction of β-catenin expression in liver cancer models. Reduction of β-catenin strongly reduced tumor burden, alone or in combination with sorafenib and as effectively as DsiRNAs that target mitotic genes such as PLK1 and KIF11. β-catenin knockdown also strongly reduced the expression of β-catenin-regulated genes, including MYC, providing a potential mechanism for tumor inhibition. These results validate β-catenin as a target for liver cancer therapy and demonstrate the promise of RNAi in general and DsiRNAs in particular for reaching traditionally undruggable cancer targets.

PMID:
24089139
PMCID:
PMC3978813
DOI:
10.1038/mt.2013.233
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center